Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study.
Kadriye Bir YücelMuzaffer UğraklıSerhat SekmekNilgun YıldırımFatih GürlerOzan YazıcıAhmet ÖzetÖznur BalMurat ArazMustafa YıldırımNuriye OzdemirPublished in: Current medical research and opinion (2024)
Beyond progression with docetaxel-based triplet chemotherapy, FOLFIRI may be preferred as a second-line treatment over paclitaxel due to its longer mPFS and mOS.
Keyphrases
- locally advanced
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- palliative care
- neoadjuvant chemotherapy
- prognostic factors
- combination therapy
- squamous cell carcinoma
- quantum dots
- radiation therapy
- room temperature
- rectal cancer
- highly efficient
- metastatic colorectal cancer
- reduced graphene oxide
- ionic liquid